Q2 2025 product sales of $18.9 million, representing 108% growth over Q2 2024 and the 18th straight quarter of sequential ...

Regulatory Interactions and Commercial, Medical and Corporate Preparations On-Track for PALSONIFY™ (paltusotine) New Drug ...

Management of classic congenital adrenal hyperplasia (CAH), a rare genetic condition diagnosed at birth, requires a careful ...

Discover Amylyx Pharmaceuticals' Q2 2025 updates, including Avexitide's Phase III progress for PBH, upcoming PSP trial results, and a strong cash ...

Xeris Biopharma reports Q2 2025 revenue up 49%, driven by Recorlev's 136% growth. Raised full-year guidance; see strong demand & pipeline opportunities.